Vitality Biopharma Developing Cannabis-derived Prodrugs for Inflammatory Bowel Disease

Vitality Biopharma Developing Cannabis-derived Prodrugs for Inflammatory Bowel Disease
VitalitylogoVitality Biopharma of California has developed a new class of cannabis-derived cannabinoid prodrugs, known as cannabosides, which can enable the selective delivery of cannabidiol (CBD), a cannabinoid compound, to the intestinal tract, and reduce the delivery of the psychoactive tetrahydrocannabinol (THC) to the brain. Vitality Biopharma, which is developing cannabinoid prodrug pharmaceuticals to treat neurological and inflammatory disorders, has released an upd
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *